These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

856 related items for PubMed ID: 30017199

  • 21. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
    Bate-Eya LT, den Hartog IJ, van der Ploeg I, Schild L, Koster J, Santo EE, Westerhout EM, Versteeg R, Caron HN, Molenaar JJ, Dolman ME.
    Oncotarget; 2016 May 10; 7(19):27946-58. PubMed ID: 27056887
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Zhao J, Niu X, Li X, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Ge Y.
    Oncotarget; 2016 Jun 07; 7(23):34785-99. PubMed ID: 27166183
    [Abstract] [Full Text] [Related]

  • 23. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
    Wang Q, Wan J, Zhang W, Hao S.
    Leuk Lymphoma; 2019 Sep 07; 60(9):2170-2180. PubMed ID: 30626241
    [Abstract] [Full Text] [Related]

  • 24. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
    Luo F, Lu FT, Qiu MZ, Zhou T, Ma WJ, Luo M, Zeng KM, Luo QY, Pan WT, Zhang L, Xia ZF, Zhang ZH, Cao JX, Zhao HY, Zhang L, Yang DJ.
    Cell Death Dis; 2021 Aug 05; 12(8):772. PubMed ID: 34354046
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP.
    Blood; 2015 Jul 16; 126(3):363-72. PubMed ID: 26045609
    [Abstract] [Full Text] [Related]

  • 26. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
    Li N, Feng L, Han HQ, Yuan J, Qi XK, Lian YF, Kuang BH, Zhang YC, Deng CC, Zhang HJ, Yao YY, Xu M, He GP, Zhao BC, Gao L, Feng QS, Chen LZ, Yang L, Yang D, Zeng YX.
    Cancer Lett; 2016 Oct 10; 381(1):14-22. PubMed ID: 27424523
    [Abstract] [Full Text] [Related]

  • 27. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D, Dousset C, Brosseau C, Touzeau C, Maïga S, Moreau P, Pellat-Deceunynck C, Le Gouill S, Amiot M.
    Oncotarget; 2015 Apr 20; 6(11):8750-9. PubMed ID: 25797245
    [Abstract] [Full Text] [Related]

  • 28. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C.
    Cancer Res; 2007 Feb 01; 67(3):1176-83. PubMed ID: 17283153
    [Abstract] [Full Text] [Related]

  • 29. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P.
    Blood; 2014 Dec 11; 124(25):3738-47. PubMed ID: 25301704
    [Abstract] [Full Text] [Related]

  • 30. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, Shellman YG.
    J Invest Dermatol; 2009 Apr 11; 129(4):964-71. PubMed ID: 18987671
    [Abstract] [Full Text] [Related]

  • 31. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
    Tamaki H, Harashima N, Hiraki M, Arichi N, Nishimura N, Shiina H, Naora K, Harada M.
    Oncotarget; 2014 Nov 30; 5(22):11399-412. PubMed ID: 25333266
    [Abstract] [Full Text] [Related]

  • 32. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
    High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB.
    Mol Pharmacol; 2010 Mar 30; 77(3):483-94. PubMed ID: 20038611
    [Abstract] [Full Text] [Related]

  • 33. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
    Zhou L, Zhang Y, Sampath D, Leverson J, Dai Y, Kmieciak M, Nguyen M, Orlowski RZ, Grant S.
    Br J Cancer; 2018 Feb 06; 118(3):388-397. PubMed ID: 29241222
    [Abstract] [Full Text] [Related]

  • 34. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE.
    Mol Pharmacol; 2009 May 06; 75(5):1231-9. PubMed ID: 19246337
    [Abstract] [Full Text] [Related]

  • 35. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
    Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, Saylors RL, Jedema I, Falkenburg JH, Chambers TC.
    Cancer Res; 2015 Apr 01; 75(7):1366-75. PubMed ID: 25649768
    [Abstract] [Full Text] [Related]

  • 36. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, Ishizawa K, Jebiwott S, Dong Y, Pietanza MC, Hellmann MD, Kris MG, Hsieh JJ, Cheng EH.
    Nat Commun; 2017 Jul 17; 8():16078. PubMed ID: 28714472
    [Abstract] [Full Text] [Related]

  • 37. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts.
    Cao LH, Li HT, Lin WQ, Tan HY, Xie L, Zhong ZJ, Zhou JH.
    Sci Rep; 2016 Jan 05; 6():18706. PubMed ID: 26729257
    [Abstract] [Full Text] [Related]

  • 38. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
    Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A, Moreau P, Pellat-Deceunynck C, Amiot M, Le Gouill S.
    Clin Cancer Res; 2011 Sep 15; 17(18):5973-81. PubMed ID: 21821698
    [Abstract] [Full Text] [Related]

  • 39. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H, Lee MH, Park I, Jeon H, Choi J, Seo S, Kim SW, Koh GY, Park KS, Lee DH.
    Cancer Lett; 2017 Dec 28; 411():19-26. PubMed ID: 28987383
    [Abstract] [Full Text] [Related]

  • 40. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
    Heinicke U, Haydn T, Kehr S, Vogler M, Fulda S.
    Oncogene; 2018 Sep 28; 37(39):5325-5339. PubMed ID: 29858601
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.